IFNα is highly effective in the treatment of myeloproliferative neoplasms (MPNs), but the mechanisms of action are unclear and it remains unknown why some patients respond to IFNα and others do not. This evidence concerns the gene IFNA2 and myeloproliferative neoplasm.